Search

Displaying results 2981 - 2990 of 8575 in total
  1. Drug

    Sacrosidase

    go.drugbank.com/drugs/DB06760
    Approved

    Sacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issue...

  2. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. … Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS).

  3. Drug

    Bucetin

    go.drugbank.com/drugs/DB13278
    ApprovedWithdrawn

    Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]

  4. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

  5. Drug

    Celiprolol

    go.drugbank.com/drugs/DB04846
    ApprovedInvestigationalWithdrawn

    In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome.

    Products: CELITIN 200MG, CELITIN 400MG
  6. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    [A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. … [L26656] Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules.

  7. Drug

    Lonafarnib

    go.drugbank.com/drugs/DB06448
    ApprovedInvestigational

    [L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549] … [A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FTI), which reduces the farnesylation of numerous cellular proteins, including progerin; as progerin farnesylation is important

  8. Drug

    Mersalyl

    go.drugbank.com/drugs/DB09338
    Experimental

    Interestingly, it has been found to have antiviral properties in mice [L1584]. … It is an outdated drug, and its approval has been discontinued by the FDA. Mersalyl acid is currently replaced by less toxic non-mercury containing diuretics [L1575, L1577].

  9. Drug

    BMS-690514

    go.drugbank.com/drugs/DB11665
    Investigational

    BMS-690514 has been investigated for the treatment of Breast Cancer.

  10. Drug

    Doxapram

    go.drugbank.com/drugs/DB00561
    ApprovedInvestigationalVet approved

    A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)